Evidence map›Paper›PMID 42573560›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Ferroptosis Suppression by the M

Ying-Qin Zhu, Yue Huang, Jing-Yuan Ye, Si-Yuan Lu, Zhi-De Liu, Ming-Jian Ma, De-Liang Fang, Zi-Yi Zhao, Jin-Zhao Xie, Jiao Chen and 1 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ying-Qin ZhuDepartment of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Yue HuangDepartment of Medical Oncology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.
Jing-Yuan YeDepartment of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Si-Yuan LuDepartment of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Zhi-De LiuDepartment of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Ming-Jian MaDepartment of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
De-Liang FangDepartment of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Zi-Yi ZhaoDepartment of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Jin-Zhao XieDepartment of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Jiao ChenDepartment of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Xiao-Yu YinDepartment of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.

Funding

China Postdoctoral Science Foundation 2024M753789Funding by Science and Technology Projects in Guangzhou 2024A04J3782Guangdong Basic and Applied Basic Research Foundation, China 2022A1515111221Guangdong Basic and Applied Basic Research Foundation, China 2023A1515110874Guangdong Basic and Applied Basic Research Foundation, China 2024A1515010487Guangdong Basic and Applied Basic Research Foundation, China 2026A1515010716National Natural Science Foundation of China 82072644National Natural Science Foundation of China 82403236National Natural Science Foundation of China 82504183National Natural Science Foundation of China 82573652Postdoctoral Fellowship Program of CPSF GZC20233243
6 · The paper itself

Abstract

aimsPancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with poor prognosis, and gemcitabine-based chemotherapy remains the standard first-line treatment. However, the rapid emergence of chemoresistance limits its efficacy. Elucidating the molecular mechanisms underlying gemcitabine resistance is critical for improving therapeutic outcomes. APPROACHES &

resultsBy integrating transcriptomic profiling of gemcitabine-resistant PDAC cells, patient-derived xenografts (PDXs), and pretreatment clinical biopsy specimens, we identified the m

conclusionsCollectively, this study uncovers a previously unrecognized epitranscriptomic mechanism linking m

Indexed as

ferroptosisFTH1IGF2BP1N6‐methyladenosinepancreatic ductal adenocarcinomastress granule

Identifiers

PMID42573560
PMCPMC13455834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.